Related Experiment Video
Updated: Jan 15, 2026

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
Prognostic Utility of Left Ventricular Ejection Fraction in Patients Undergoing Transcatheter Aortic Valve
Yosuke Nabeshima1, Tetsuji Kitano2, Yoshiko Sakamoto1
1Department of Cardiovascular Medicine, Saga University Saga Japan.
Insights
Reduced left ventricular ejection fraction (LVEF) before transcatheter aortic valve implantation (TAVI) predicts worse outcomes. This finding emphasizes LVEF
Area of Science:
- Cardiology
- Medical Imaging
- Clinical Outcomes
Background:
- Left ventricular ejection fraction (LVEF) assesses systolic function but its prognostic value in transcatheter aortic valve implantation (TAVI) patients is unclear.
- Current guidelines lack definitive recommendations on LVEF's role in TAVI risk stratification.
- Uncertainty exists regarding LVEF's predictive accuracy for cardiovascular outcomes post-TAVI.
Purpose of the Study:
- To systematically review and meta-analyze the association between preprocedural LVEF and outcomes following TAVI.
- To clarify the prognostic significance of LVEF in patients undergoing TAVI.
- To assess potential effect modifiers on the LVEF-outcome relationship.
Main Methods:
- Systematic review and meta-analysis of studies from 2001-2024.
- Searched PubMed and Scopus for studies reporting hazard ratios for preprocedural LVEF.
- Included 92 studies (98 cohorts, 75,085 patients); used random-effects models for analysis.
- Conducted subgroup and meta-regression analyses to explore effect modification.
Main Results:
- Each 1% decrease in LVEF was linked to increased adverse events (HR 1.02; 95% CI: 1.01-1.03), persisting after confounder adjustment.
- Association remained robust across various subgroups and settings.
- Meta-regression indicated stronger LVEF-outcome association in lower baseline LVEF groups, attenuated in preserved LVEF cohorts.
Conclusions:
- Preprocedural reduced LVEF independently predicts worse prognosis after TAVI.
- LVEF remains crucial for risk stratification and clinical decisions in TAVI candidates.
- The prognostic impact of LVEF may be modulated by baseline ventricular function.
Background:
Left ventricular ejection fraction (LVEF) is widely used to assess systolic function and to predict cardiovascular outcomes, but its prognostic role in patients undergoing transcatheter aortic valve implantation (TAVI) remains uncertain.
Methods And Results:
We performed a systematic review and meta-analysis of studies published from 2001 to 2024 that evaluated the association between preprocedural LVEF and post-TAVI outcomes. Eligible studies were identified via PubMed and Scopus, and included those reporting hazard ratios for preprocedural LVEF. A total of 92 studies comprising 98 patient cohorts and 75,085 individuals were included. Random-effects models were used for univariable and multivariable analyses. Subgroup and meta-regression analyses assessed effect modifiers, including ethnicity, LVEF classification, endpoints, and study design. Each 1% decrease in LVEF was associated with an increased risk of adverse events (hazard ratio 1.02, 95% confidence interval: 1.01-1.03), and this association remained significant after adjusting for confounders. Subgroup analyses confirmed the robustness of this association in various settings. In the multivariable meta-regression, studies with lower mean LVEF demonstrated a stronger association between reduced LVEF and adverse outcomes, but this association was attenuated or nonsignificant in cohorts with preserved systolic function. This suggests that the prognostic value of LVEF may depend on the baseline level of ventricular function and is subject to effect modification.
Conclusions:
Reduced preprocedural LVEF is independently associated with worse prognosis after TAVI. These results highlight the continued importance of LVEF in risk stratification and clinical decision-making in TAVI candidates.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse II: Assessment and Management
Aortic Regurgitation III: Medical Management

